Sweden

Dela

Välj datumintervall -
Taggar ( valda)

Qlife enters fully funded feasibility agreement with global pharma company for Egoo Health biomarker application

Qlife Holding AB (“Qlife” or the “Company”), a pioneer in clinical-grade home diagnostics, announces that it has entered into a feasibility agreement with a global pharmaceutical company with the objective to evaluate a specific biomarker on Egoo Health related to a therapeutic application. The feasibility agreement is fully funded by the pharma company.The feasibility study represents a first step toward a potential collaboration focused on dedicated R&D and regulatory proceedings and future supply of Egoo Health systems for the targeted application. While the pharmaceutical partner

Kommuniké från årsstämma 2026 i Qlife Holding AB

Qlife Holding AB höll den 27 maj 2026 årsstämma varvid i huvudsak följande beslut fattades.Fastställande av räkenskaper samt resultatdisposition Årsstämman beslutade att fastställa resultat- och balansräkning samt koncernresultat- och koncernbalansräkning. Årsstämman beslutade även att disponera över bolagets resultat i enlighet med styrelsens förslag innebärande att någon utdelning inte lämnas och att bolagets medel till förfogande överförs i ny räkning. Ansvarsfrihet Stämman beslutade att bevilja samtliga som under 2025 innehaft uppdrag som styrelseledamot eller verkställande

QLIFE HOLDING AB, Interim Report Q1, January - March 2026

Approaching strategic partnershipsThe full report is attached and can also be found here: https://qlifeholding.com/en/investors/finansiella-rapporter Financial summary – first quarter 2026 · Revenue in the period amounted to kSEK 21 (110). · EBITDA for the period amounted to kSEK –5,502 (–5,269 ), and net loss kSEK -6,225 (-6,120) · The total cash flow in the first quarter amounted to kSEK 5,387 (-8). · Earnings per share before/after dilution for the quarter amounted to SEK -0.73 (-0.73), calculated on weighted average number of shares in the period. Significant events –

Kallelse till årsstämma 2026 i Qlife Holding AB

Aktieägarna i Qlife Holding AB, org.nr 559224-8040, kallas till årsstämma den 27 maj 2026 kl. 11.00 i Moll Wendén Advokatbyrås lokaler på Stortorget 8 i Malmö.Rätt att delta och anmälan Den som önskar delta i stämman ska: · dels vara upptagen som aktieägare i den av Euroclear Sweden AB framställda aktieboken avseende förhållanden på avstämningsdagen som är den 19 maj 2026, · dels anmäla sig till stämman senast den 21 maj 2026. Anmälan görs per post till Moll Wendén Advokatbyrå, Qlife AGM, Stortorget 8, 211 34 Malmö eller per e-post till QlifeAGM@mollwenden.se. I anmälan bör

The ISP leaves notifications under the FDI Act without action in connection with allotment to certain investors in Qlife's rights issue

NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION, DIRECTLY OR INDIRECTLY, IN OR INTO, THE UNITED STATES OF AMERICA, AUSTRALIA, BELARUS, CANADA, HONG KONG, JAPAN, NEW ZEALAND, RUSSIA, SINGAPORE, SOUTH AFRICA, SOUTH KOREA, SWITZERLAND OR ANY OTHER JURISDICTION IN WHICH THE RELEASE, DISTRIBUTION OR PUBLICATION WOULD BE UNLAWFUL OR REQUIRE REGISTRATION OR ANY OTHER MEASUREQlife Holding AB (“Qlife” or the “Company”) announces that the Swedish Inspectorate of Strategic Products (“ISP”) has decided to leave without action the notifications filed under the Swedish Act (2023:560) on the Screening of

Qlife announces the last day of trading in BTA

NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION, DIRECTLY OR INDIRECTLY, IN OR INTO, THE UNITED STATES OF AMERICA, AUSTRALIA, BELARUS, CANADA, HONG KONG, JAPAN, NEW ZEALAND, RUSSIA, SINGAPORE, SOUTH AFRICA, SOUTH KOREA, SWITZERLAND OR ANY OTHER JURISDICTION IN WHICH THE RELEASE, DISTRIBUTION OR PUBLICATION WOULD BE UNLAWFUL OR REQUIRE REGISTRATION OR ANY OTHER MEASUREThe rights issue that was announced by Qlife Holding AB (publ) (“Qlife” or the “Company”) on 22 January 2026, which was approved by an extraordinary general meeting on 26 February 2026 (the “Rights Issue”), has been partially

Qlife announces the outcome of the rights issue and resolves on a directed issue of shares to guarantors

NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION, DIRECTLY OR INDIRECTLY, IN OR INTO, THE UNITED STATES OF AMERICA, AUSTRALIA, BELARUS, CANADA, HONG KONG, JAPAN, NEW ZEALAND, RUSSIA, SINGAPORE, SOUTH AFRICA, SOUTH KOREA, SWITZERLAND OR ANY OTHER JURISDICTION IN WHICH THE RELEASE, DISTRIBUTION OR PUBLICATION WOULD BE UNLAWFUL OR REQUIRE REGISTRATION OR ANY OTHER MEASUREOn 22 January 2026, Qlife Holding AB (“Qlife” or the “Company”) announced a rights issue of approximately SEK 31.4 million, which was approved by an extraordinary general meeting on 26 February 2026 (the “Rights Issue”). The

Qlife provides business update on clinical progress, partnerships and commercialization initiatives

Qlife Holding AB (“Qlife” or the “Company”), a pioneer in clinical-grade home diagnostics, today provides a business update covering recent milestones, ongoing progress, and priorities for the coming quarters.Clinical validation and regulatory progress Qlife has continued to strengthen the clinical foundation for the Egoo platform. The Company recently published results from the Birmingham PKU study, demonstrating that Egoo performs reliably in real-life settings. Following this milestone, Qlife has also submitted the Egoo Phe system for regulatory approval. In parallel, Qlife has

The subscription period in Qlife’s rights issue ends on Thursday, 19 March 2026

NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION, DIRECTLY OR INDIRECTLY, IN OR INTO, THE UNITED STATES OF AMERICA, AUSTRALIA, BELARUS, CANADA, HONG KONG, JAPAN, NEW ZEALAND, RUSSIA, SINGAPORE, SOUTH AFRICA, SOUTH KOREA, SWITZERLAND OR ANY OTHER JURISDICTION IN WHICH THE RELEASE, DISTRIBUTION OR PUBLICATION WOULD BE UNLAWFUL OR REQUIRE REGISTRATION OR ANY OTHER MEASUREThursday, 19 March 2026, is the last day of the subscription period in Qlife Holding AB’s (“Qlife” or the “Company”) rights issue of approximately SEK 31.4 million (the “Rights Issue”). Please note that some banks and brokers may

Hipro to accelerate Egoo development and regulatory approval in China following strong interest

Qlife Holding AB (“Qlife” or the “Company”) today announces that, following the recently communicated strong interest from hospitals in China in evaluating the Egoo platform, its strategic partner Hipro Biotechnology will accelerate the path towards commercialisation based on its full responsibility for the continued development, local adaptation, regulatory approval of Egoo in China.Under the agreed structure, Hipro will manage product development activities, regulatory submissions, manufacturing, and commercialization in the Chinese market. Qlife will receive a royalty of 20 percent on

The subscription period in Qlife’s rights issue begins today

NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION, DIRECTLY OR INDIRECTLY, IN OR INTO, THE UNITED STATES OF AMERICA, AUSTRALIA, BELARUS, CANADA, HONG KONG, JAPAN, NEW ZEALAND, RUSSIA, SINGAPORE, SOUTH AFRICA, SOUTH KOREA, SWITZERLAND OR ANY OTHER JURISDICTION IN WHICH THE RELEASE, DISTRIBUTION OR PUBLICATION WOULD BE UNLAWFUL OR REQUIRE REGISTRATION OR ANY OTHER MEASUREToday, 5 March 2026, is the first day of the subscription period in Qlife Holding AB's (“Qlife” or the “Company”) issue of a maximum of 15,679,521 shares with preferential rights for existing shareholders at a subscription price

Qlife publishes information document due to upcoming rights issue

NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION, DIRECTLY OR INDIRECTLY, IN OR INTO, THE UNITED STATES OF AMERICA, AUSTRALIA, BELARUS, CANADA, HONG KONG, JAPAN, NEW ZEALAND, RUSSIA, SINGAPORE, SOUTH AFRICA, SOUTH KOREA, SWITZERLAND OR ANY OTHER JURISDICTION IN WHICH THE RELEASE, DISTRIBUTION OR PUBLICATION WOULD BE UNLAWFUL OR REQUIRE REGISTRATION OR ANY OTHER MEASUREQlife Holding AB (“Qlife” or the “Company”) publishes an information document regarding the Company's new share issue with preferential rights for existing shareholders of approximately SEK 31.4 million, which was resolved by the

Qlife announces that two investors have entered agreements to subscribe for shares if the rights issue is subscribed below approx. 51.0 percent, taking over commitments from a group of guarantors

NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION, DIRECTLY OR INDIRECTLY, IN OR INTO, THE UNITED STATES OF AMERICA, AUSTRALIA, BELARUS, CANADA, HONG KONG, JAPAN, NEW ZEALAND, RUSSIA, SINGAPORE, SOUTH AFRICA, SOUTH KOREA, SWITZERLAND OR ANY OTHER JURISDICTION IN WHICH THE RELEASE, DISTRIBUTION OR PUBLICATION WOULD BE UNLAWFUL OR REQUIRE REGISTRATION OR ANY OTHER MEASUREQlife Holding AB (publ) (“Qlife” or the “Company”) today announces that Jinderman & Partners AB and JJV Investment Group AB (the “Investors”) have entered into agreements to subscribe for shares if the Company’s rights issue,

Kommuniké från extra bolagsstämma 2026 i Qlife Holding AB

Qlife Holding AB (”Bolaget” eller ”Qlife”) höll den 26 februari 2026 extra bolagsstämma varvid i huvudsak följande beslut fattades.Beslut om ändring av bolagsordningen Den extra bolagsstämman beslutade, i enlighet med styrelsens förslag, att bolagsordningens gränser för aktiekapital och antal aktier ändras i enlighet med nedan. Nuvarande lydelse Föreslagen ändrad lydelse§ 4 § 4 AktiekapitalAktiekapitalet ska uppgå tillAktiekapitalAktiekapitalet lägst 2 500 000 kronor och högst 10 000 000ska uppgå till kronor.lägst 1 112 000

Qlife launches pharmacy pilot project in Nordic markets

Qlife Holding AB (“Qlife” or the “Company”), a pioneer in clinical-grade home diagnostics, today announces that the previously communicated pilot project for blood testing in pharmacies has now been launched. The pilot is being initiated in selected pharmacies in the Nordic region and represents an important step in Qlife’s strategy to expand into decentralized healthcare settings.The pilot is designed to evaluate the integration of Qlife’s and Hipro’s point-of-care testing solutions within the pharmacy environment, including workflow, training, and patient uptake. The objective is to

Guarantor converts guarantee commitment of SEK 0.5 million into binding subscription commitment and top guarantor waives guarantee compensation in Qlife’s ongoing rights issue

NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION, DIRECTLY OR INDIRECTLY, IN OR INTO, THE UNITED STATES OF AMERICA, AUSTRALIA, BELARUS, CANADA, HONG KONG, JAPAN, NEW ZEALAND, RUSSIA, SINGAPORE, SOUTH AFRICA, SOUTH KOREA, SWITZERLAND OR ANY OTHER JURISDICTION IN WHICH THE RELEASE, DISTRIBUTION OR PUBLICATION WOULD BE UNLAWFUL OR REQUIRE REGISTRATION OR ANY OTHER MEASUREQlife Holding AB (publ) (“Qlife” or the “Company”) today announces changes to the commitment structure in the ongoing rights issue, announced by the Company on 22 January 2026. Guarantor John Bäck has converted his guarantee

QLIFE HOLDING AB, Interim Report Q4, October - December 2025

Positioned for scale in 2026 The full report is attached and can also be found here: https://qlifeholding.com/en/investors/finansiella-rapporterFinancial summary – fourth quarter 2025 · On 5. October Qlife extends the Letter of Intent with Hipro Biotechnology Co., Ltd. regarding reverse takeover. The term and exclusivity of the Letter of Intent have been extended, and the Transaction would be conditional upon, inter alia, the signing of a share purchase agreement no later than 31 December 2025. The other material terms and conditions of the Transaction as previously communicated by

Kallelse till extra bolagsstämma 2026 i Qlife Holding AB

Aktieägarna i Qlife Holding AB, org.nr 559224-8040, kallas till extra bolagsstämma den 26 februari 2026 kl. 10.00 i Moll Wendén Advokatbyrås lokaler på Stortorget 8 i Malmö. Rätt att delta och anmälan Den som önskar delta i stämman ska: · dels vara upptagen som aktieägare i den av Euroclear Sweden AB framställda aktieboken avseende förhållanden på avstämningsdagen som är den 18 februari 2026, · dels anmäla sig till stämman senast den 20 februari 2026. Anmälan görs per post till Moll Wendén Advokatbyrå, Extra bolagsstämma, Stortorget 8, 211 34 Malmö eller per e-post till

Qlife submits Egoo PHE home testing system for regulatory approval

Qlife Holding AB (“Qlife” or the “Company”), a pioneer in clinical-grade home diagnostics, today announces that the Company has formally submitted its Egoo PHE home‑testing system for regulatory approval to the relevant Notified Body and authorities. This marks a major milestone in Qlife’s mission to make high‑quality, decentralized testing for Phenylalanine (PHE) available for patients living with Phenylketonuria (PKU).The submission follows the recently published clinical trial results from Birmingham Women’s and Children’s NHS Foundation Trust, which demonstrated strong performance in

Qlife resolves on a partially guaranteed rights issue of approx. SEK 31.4 million and proposes an over-allotment option, enters bridge loan agreements and postpones the exercise period of warrants TO7

NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION, DIRECTLY OR INDIRECTLY, IN OR INTO, THE UNITED STATES OF AMERICA, AUSTRALIA, BELARUS, CANADA, HONG KONG, JAPAN, NEW ZEALAND, RUSSIA, SINGAPORE, SOUTH AFRICA, SOUTH KOREA, SWITZERLAND OR ANY OTHER JURISDICTION IN WHICH THE RELEASE, DISTRIBUTION OR PUBLICATION WOULD BE UNLAWFUL OR REQUIRE REGISTRATION OR ANY OTHER MEASUREToday, the Board of Directors in Qlife Holding AB (“Qlife” or the “Company”) has, subject to the approval of an extraordinary general meeting (the “EGM”), resolved to carry out an issue of 15,679,521 shares with preferential

Qlife prepares for pharmacy testing in Nordic markets

Qlife Holding AB (“Qlife” or the “Company”), a pioneer in clinical-grade home diagnostics, is preparing a pilot project for blood testing in pharmacies across Denmark, Sweden and the UK. Inspired by the success of the UK’s Pharmacy First program, which has now been in operation for a few years and demonstrated significant benefits for both patients and the healthcare system, Qlife is now executing on its plans to bring its blood testing platforms to the pharmacy sector.Pharmacies are expected to play an increasingly important role in healthcare, with blood testing now paving the way for

Egoo Health achieves breakthrough precision in key diabetes biomarker test, paving the way for partnerships

Qlife Holding AB (“Qlife” or the “Company”), a pioneer in clinical-grade home diagnostics, together with its partner Hipro Biotechnology Co., Ltd. (“Hipro”), announces a major milestone: the Egoo HbA1c blood test for diabetes management has achieved best-in-class precision with a coefficient of variation (CV) below 3%. This achievement positions Egoo optimally for partnering and commercialisation potentially, the first home-use HbA1c test to meet the same stringent clinical and regulatory standards as central laboratory testing.Managing diabetes at home requires solutions that are accurate,

Det finns inga träffar som matchar nuvarande filter
Det finns inga fler träffar som matchar nuvarande filter
Tillbaka till sidans topp

Prenumerera